# Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia

> **NCT06990321** · PHASE3 · RECRUITING · sponsor: **Yehui Tan** · enrollment: 68 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Elderly

## Interventions

- **DRUG:** Intermediate-dose Cytarabine in Combination with Venetoclax

## Key facts

- **NCT ID:** NCT06990321
- **Lead sponsor:** Yehui Tan
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06990321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06990321, "Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06990321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*